Amarin Defends Patent Ruling on Skinny Labels, Mitigates Impact on Generic Drugmakers

Amarin Pharma Inc., a pharmaceutical company known for its cardiovascular drug Vascepa, has defended a Federal Circuit decision that rejuvenates its patent case involving “skinny labels” against a competing U.K. drugmaker. The term “skinny label” refers to drug labeling that omits certain uses that are still protected by patents. This legal strategy allows generic drugmakers to enter the market with versions of a brand-name drug without infringing on patents that cover some specific uses. The company reassures the appeals court that the implications of this decision will not result in detrimental effects on the generic pharmaceutical industry. For more details on this legal development, you can read the article on Law360.